Stockreport

Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – Four-year follow-up analysis from the Phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic le [Read more]